Merck's drug, Keytruda, reduced the risk of death in the trial by 51 percent when combined with chemotherapies, versus chemo alone.
Bristol's drug, Opdivo, along with another of its medicines, Yervoy, reduced the risk of cancer progression or death in its study by 42 percent when compared with chemo.
